Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted ...

Barclays raised the firm’s price target on Boston Scientific (BSX) to $118 from $111 and keeps an Overweight rating on the shares. The firm ...

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...

Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a ...

Boston Scientific’s BSX robust expansion of operations ... Australia, New Zealand and Canada), which are holding strong growth potentials based on their economic conditions, healthcare sectors ...

Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.